Soluble PD-1 Is a Potential Biomarker in Metastatic Melanoma in Patients Treated With Autologous Vaccines

Source: Cancer Therapy Advisor, November 2019

Research on programmed-death 1 (PD-1) found on T cells and its receptor, programmed-death ligand 1 (PD-L1), found in varying levels on tumor is a central topic in immunotherapy. However, comparatively little research has been done on the soluble version of the protein (sPD-1) found in blood plasma.

Now a new study, published in the journal Oncotarget,1has assessed sPD-1 levels in patients with metastatic melanoma, before and after treatment with patient-specific autologous cancer vaccines.

“Probably 99% of the papers on PD-1 revolve around PD-1 expressed on the surface of T cells; this sPD-1 variant has been basically ignored in the meantime. It’s a very understudied area,” said Eric Bartee, PhD, associate professor in the department of microbiology and immunology at the Medical University of South Carolina, Charleston.

Read the original full article

2019 Events

Calculate your risk of getting melanoma Sunscreen calculator
Map of body for recording areas of skin causing you concern on your body Target Therapy Finder